NCT01870895

A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)

A Double-blind, Parallel-group, Comparative Study in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 577 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: Female
• Age: 20 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

To demonstrate the superiority of YM060 to a placebo in global assessment of relief of overall IBS symptoms and stool form normalization, and to evaluate safety in female patients with diarrhea-predominant irritable bowel syndrome (D-IBS).

Conditions

• Diarrhea-predominant Irritable Bowel Syndrome

Interventions

Type	Name	Description
DRUG	YM060	oral
DRUG	Placebo	oral

Timeline

• Start date: 2013-02-01
• Primary completion: 2014-02-01
• Completion: 2014-02-01
• First posted: 2013-06-06
• Last updated: 2015-10-12

Locations

4 sites across 1 country: Japan